Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17395944 | 0.88 | OGT (0.60) | OGTTSHRALDH1A1NPSR1MAPT | |
| SCHEMBL21789039 | 0.86 | MAPT (0.44) | OGTTSHRALDH1A1NPSR1MAPT | |
| SCHEMBL21777359 | 0.86 | MAPT (0.47) | OGTTSHRALDH1A1NPSR1MAPT | |
| SCHEMBL21777358 | 0.86 | MAPT (0.47) | OGTTSHRALDH1A1NPSR1MAPT | |
| SCHEMBL21788946 | 0.83 | ALDH1A1 (0.45) | OGTTSHRALDH1A1NPSR1MAPT | |
| SCHEMBL17406950 | 0.81 | CTSK (0.48) | OGTTSHRALDH1A1NPSR1HPGD | |
| SCHEMBL21777440 | 0.79 | PPARG (0.42) | OGTTSHRALDH1A1NPSR1MAPT | |
| SCHEMBL21777274 | 0.76 | ALDH1A1 (0.41) | OGTALDH1A1NPSR1MAPTPOLB | |
| SCHEMBL23357774 | 0.75 | CTSK (0.46) | TSHRALDH1A1NPSR1MAPTPOLB | |
| SCHEMBL21939465 | 0.74 | CTSK (0.51) | TSHRALDH1A1NPSR1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2016004180-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | OGT 2/4885TSHR 3248/4885ALDH1A1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.